Generic Drugs Are the Prescription for Savings. Don’t Take Them for Granted.
More than 9 out of 10 generic drug prescriptions are filled for $20 or less. Everybody who takes medicine to get or stay healthy can appreciate these savings, which allow patients and families to spend their money on other things that matters to them. Those savings, however, are now in jeopardy, thanks to a combination […]
Protect & Expand Competition
Generic and biosimilar medicines are saving families money and holding down government costs. The Association for Accessible Medicines (AAM), formerly known as the Generic Pharmaceutical Association, advocates for policies that ensure real competition not half-measures or window dressing. When we stop some brand drug companies from blocking or delaying competition from safe, effective and more […]
Generic Drug Prices vs. Brand Drug Prices
According to FDA estimates, generics are 80%-85% less expensive than their brand-name drug equivalents. Competition and a patient-centered orientation are what make generics and biosimilars the solution that helps people live their lives, their way. The Association for Accessible Medicines and its members give millions of Americans what they need to need to live healthier, […]
Generics: Your Prescription for Savings
More FDA-approved generic and biosimilar medicines are available now than ever before. Today, America’s patients are benefitting from significant savings at the pharmacy counter and in lower out-of-pocket costs. But those savings are increasingly at risk due to anti-competitive abuses and misguided policies that block access to lower-cost medicines. Congress can take meaningful action to […]
How to Talk About Drug Prices
A Reference Guide for Lawmakers The rising cost of prescription drugs is a top issue for voters this election cycle. AAM developed a resource for lawmakers, “How to Talk About Drug Prices: A Reference Guide for Effective Communications Strategy.” This primer on rising drug costs outlines how high launch prices and year-over-year price increases are […]
AAM Statement: Preserving Patient Access to Low-Cost Medicines Through COVID-19 and Beyond
WASHINGTON, DC (March 24, 2020) — The Association for Accessible Medicines (AAM) and its member companies express our steadfast support for all who are battling COVID-19, from the patients diagnosed with the disease to the health care professionals providing their care. For our part, generic and biosimilar manufacturers are committed to serving as a trusted […]
The First (Price) Cut Is the Steepest
Congress Must Preserve the 180-Day Incentive for First Generics In the debate over how to lower the cost of prescription drugs, one thing is certain: Generic competition drives savings for America’s patients and our health care system. The introduction of generic medicines offers patients the same high-quality medicine as the brand-name drug, but at an […]
Savings by Condition: The Latest Data
How much do you save when you treat your health conditions using generic drugs? The “Case for Competition”—the 11th annual edition of our Savings and Access Report—explores how generics and biosimilars bring down overall health care costs. To supplement the data in the report, the Association for Accessible Medicines (AAM) has also gathered information specific […]
AAM Statement on Avalere Analysis of Generic Substitution
WASHINGTON DC (January 23, 2020) –“Today’s report highlights the need to refine the Medicare program to support savings through generic drug substitution. The continued use of high-cost brand drugs instead of generics causes higher spending for patients and taxpayers.” ATTRIBUTE TO: Chip Davis, President and CEO Read White Paper MEDIA CONTACT: Rachel Schwartz 202.249.7147 […]
AAM Statement on “The Unintended Economics of the BLOCKING Act” Report
WASHINGTON DC (January 8, 2020) – New analysis from Matrix Global Advisors estimates the delay of just one generic medicine will increase prescription drug costs for patients by $1.7 billion. Congress should take the significant economic impact of the BLOCKING Act into account and reevaluate the need for this legislation. Without changes, the BLOCKING Act threatens […]
AAM Statement on HR 3
The Elijah E. Cummings Lower Drug Costs Now Act WASHINGTON DC (December 13, 2019) – AAM commends the House for its efforts to address the high cost of brand-name drugs and improve the Medicare program for seniors. Generics and biosimilars are vital to reducing spending for patients and taxpayers, and any inflation-based rebates should acknowledge the […]
AAM Opposes the Lower Health Care Costs Act
Legislation will harm generic drug competition WASHINGTON DC (December 9, 2019) – “AAM opposes the Lower Health Care Costs Act, because its inclusion of the BLOCKING Act will reduce generic drug competition, result in fewer affordable generic medicines being available to patients and thus will keep drug prices high. AAM has offered numerous alternatives to […]
